George Gemayel, Ph.D, has served as a member of our Board since 2015 and has served as consultant for several biotechnology companies and venture capital funds since 2010. From February 2011 to December 2012, Dr. Gemayel served as Executive Chairman of Syndexa Pharmaceuticals Corp., a privately held drug development company. In 2010, Dr. Gemayel served as Executive Chairman of FoldRx until its acquisition by Pfizer. From June 2008 until November 2009, Dr. Gemayel served as President and CEO of Altus Pharmaceuticals, a publicly traded pharmaceutical company. From 2003 to 2008, he was Executive Vice President at Genzyme Corporation, where he was responsible for Genzyme’s global therapeutics, transplant, renal and biosurgery business. From 2000 to 2003, Dr. Gemayel was employed as Vice President of National Specialty Care for Hoffmann La-Roche, responsible for its U.S. business for dermatology, oncology, transplantation, hepatitis, and HIV. Dr. Gemayel joined Hoffman La-Roche in 1988 and served in various positions of increasing responsibility over his tenure. Dr. Gemayel received his Doctorate in Pharmacy from Saint Joseph University in Beirut, Lebanon and his PhD in Pharmacology from Paris-Sud University in Paris, France. Dr. Gemayel currently serves as Chairman of the board of directors of Enterome Bioscience SA and GlycoEra AG (both privately held companies), as well as serving as a director of Disc Medicine Inc. and of Flamingo Therapeutics (both privately held companies). He was previously a Director of Adcolor Corporation, a publicly traded company acquired by Cubis Pharmaceuticals, Inc., a Director at Prosena, acquired by Biomarin, a Director at NPS, acquired by Shire, a Director of EpiTherapeutics, acquired by Gilead, and the Chairman of Vascular Magnetics, a privately owned company. Dr. Gemayel’s substantial experience on the Board of Directors of life science and healthcare companies and his over 25 years of experience in the pharmaceutical industry, including management and executive positions spanning the United States, Europe, and the Middle East, qualify him to serve as a director.

Charles W. Newhall, III, has served as a member of our Board since 2005. In 1977, Mr. Newhall co-founded NEA, a venture capital firm that focuses on the medical and life sciences and information technology industries, from which he retired effective December 31, 2012. To date, Mr. Newhall has served as a director of over 60 venture-backed companies. Some of his current Board memberships include NeuroPace, Inc. and Interfusion. In 1986, he founded the Mid-Atlantic Venture Capital Association (MAVA), which now has a membership of 500 venture capital firms, and is one of the most active regional venture associations in the country. He is Chairman Emeritus of MAVA. He has served as an advisor to Greenspring Associates since 2012. Before NEA, Mr. Newhall was a Vice President of T. Rowe Price. He served in Vietnam commanding an independent platoon including an initial reconnaissance of Hamburger Hill. His decorations include the Silver Star, Bronze Star V (1st OLC), and the Purple Heart. He earned an Honors Degree in English from the University of Pennsylvania and an MBA from Harvard Business School. Mr. Newhall’s substantial experience with companies in the healthcare sector and his venture capital, financial, and business experience qualify him to serve as a director.

Jack A. Khattar is the founder of our company and has served as our President, Chief Executive Officer, and Director since 2005. From 1999 to 2005, Mr. Khattar served in various positions during that time as a Board member, President and CEO of Shire Laboratories Inc., the drug delivery subsidiary of Shire plc. From 1999 to 2004, he also served as a member of Shire plc’s Executive Committee. Prior to that, Mr. Khattar served as an Executive Officer and the Chairman of the Management Committee at CIMA Labs Inc. (CIMA), a drug delivery company where he was also responsible for business development, corporate alliances and strategic planning. Prior to joining CIMA in 1995, Mr. Khattar held several marketing and business development positions at Merck & Co., Novartis, Playtex and Kodak in various locations, including the United States, Europe and the Middle East. Mr. Khattar served on the Board of Rockville Economic Development, Inc. from 2003 to 2013. He currently serves on the Board of Directors of Prevacus, Inc., a privately-held development stage biotechnology company, and is also Chairman of the Board of scPharmaceuticals, a publicly traded biotechnology company. Mr. Khattar earned his degrees in Marketing with a BBA from American University of Beirut and an MBA from the Wharton School of the University of Pennsylvania. Mr. Khattar’s leadership, executive, managerial, business and pharmaceutical company experience, along with his more than 25 years of industry experience in the development and commercialization of pharmaceutical products and drug delivery technologies, qualify him to be a director.

Frederick M. Hudson has served as a member of our Board and chair of the Audit Committee since 2010. Mr. Hudson retired as a partner in the accounting firm of KPMG LLP in 2006 after a 37-year career with the firm. He was the partner in charge of the health care audit practice for the Washington-Baltimore business unit and held leadership positions within the mergers and acquisitions and venture capital services unit. Mr. Hudson currently chairs the audit committee of the board of directors of scPharmaceuticals, Inc., a publicly traded pharmaceutical company. From 2014-2019, he was a member of the Board of Directors of Aradigm Corporation and chair of the audit committee. He is a director of GBMC Healthcare, Inc. and its affiliate, Greater Baltimore Medical Center, serving as chair of the board from 2019-2022, and previously as chair of the finance committee and audit committee. Other previous directorships include: director and compliance committee member of Maxim Healthcare Services; Board of Directors member and audit committee chair of Educate, Inc., Woodhaven Holding Corp., Vicor Technologies, Inc., and Paradigm Management Services, LLC. He served on the Board of Financial Administration of the Catholic Archdiocese of Baltimore and on the Board of Trustees of the Maryland Historical Society. Mr. Hudson received a B.S. in Accounting from Loyola University Maryland and is a Certified Public Accountant (retired). Mr. Hudson’s extensive accounting and health care audit experiences qualify him to serve as a director.